After garnering a total of $232 million in venture funds to buy aaiPharma's pharmaceutical division out of bankruptcy, Xanodyne Pharmaceuticals--which has three products in development in addition to a number of marketed pharmaceuticals--is now planning to go public, filing an $86.2 million IPO. Apax Partners, MPM Capital, AIG, Essex Woodlands Health Ventures, HealthCare Ventures, Aisling Capital and Blue Chip Venture all have a stake in the company. Release